Nicox’s Licensee Bausch + Lomb Launches VYZULTA in Mexico Paris Stock Exchange:COX

Press Release Nicox’s Licensee Bausch + Lomb Launches VYZULTA^® in Mexico  

January 6, 2021  – release at 7:30 am CET
Sophia Antipolis, France                                                                  

 

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that an affiliate of its licensee, Bausch + Lomb, has launched VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024% in Mexico.  Approval was obtained in Mexico in January 2020.

 

First approved by the U.S. Food and Drug Administration in late 2017, VYZULTA is now commercialized in the United States, Canada, Argentina and Mexico.  It is also approved in 4 other territories – Colombia, Hong Kong, Taiwan and Ukraine – and is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.  Bausch Health Companies Inc. (NYSE/TSX: BHC) and its leading global eye health business, Bausch + Lomb, will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application, can be used for approval by the regulatory authorities.

 

Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestones payments.

 

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.  Nicox generates revenue from VYZULTA^® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. 

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage  

Bryan, Garnier & Co        Victor Floc’h           Paris, France
Cantor Fitzgerald             Louise Chen           New York, U.S.
H.C. Wainwright & Co      Yi Chen                   New York, U.S.
Kepler Cheuvreux             Damien Choplain   Paris, France
Oppenheimer & Co          Hartaj Singh            New York, U.S.

  The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current.  Nicox disavows any obligation to correct or to update the information contained in analyst reports.

 

Contacts Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development 
T +33 (0)4 97 24 53 00
[email protected] Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
[email protected] Media
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
[email protected] Forward-Looking Statements The information contained in this document may be modified without prior notice.  This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.  These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3^rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox’s website (www.nicox.com) and in the 4^th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox’s website..

Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99